Official UK procurement notice
Meningitis B Vaccine (2026)
Authority: Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency (Central government)·Consortium: 2 public authorities
What is being bought
Published requirement descriptionThe provision of a vaccine to protect against meningococcal B (MenB) disease, to be used in the national childhood immunisation programme, as well as a targeted programme to protect at risk adults against Gonorrhoea.
Value - The contract value is withheld from publication pursuant to regulation 94(2)(b) of the Procurement Act 2023, so as not to prejudice the legitimate commercial interest of the supplier.
The lotProcurement structure
single lot · no lot value publishedLot #1Awarded
Procedure terms & legal framework
From the official record- Procedure method
- Direct award
- Legal basis
- UKPGA · 2023/54 Procurement Act 2023
- Notice status
- Awarded without competition
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Stand-alone contract (no framework)
- Competition type
- Direct award (no call for competition)
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 9 Sept 2025, 11:08 BST
- Last source update
- 30 Jun 2026, 11:02 BST
- Authority reference
C352798- FTS notice number
2026/S 000-061108- Latest notice
- Contract details notice (UK7)
- Delivery area
- Official registry OCID
ocds-h6vhtk-059678Find a Tender
- Why no open competition
- Single Suppliers Intellectual Property Exclusive Rights
- Published justification
The following conditions are met in relation to the public contract under Schedule 5, Paragraph 5 (a, b) of the Procurement Act 2023-
(a) due to a particular supplier having intellectual property rights or other exclusive rights, only that supplier can supply the goods, services or works required, and
(b)there are no reasonable alternatives to those goods, services or works.
- Risks
The below known unknown risks have been identified, which may require modification of the contract under paragraph 5 of Schedule 8 to the PA 2023 if one of the below identified risks materialise.
Risk 1:
The COVID-19 pandemic led to lockdown events, which disrupted the distribution and uptake of some national immunisation campaigns. The forecast delivery and stock requirements were substantially changed as a result. An ongoing risk is the materialisation of a UK health emergency or global pandemic, which may materialise in any given year.
How the risk may impact on the performance of the contract:
A health emergency or pandemic may materially affect the uptake of the MenB vaccine. Continued delivery of the vaccine within the original term of the contract could jeopardise stock management and effective use of vaccines before expiry.
Why is it not possible to address the potential impact of such risks?
UKHSA and suppliers cannot reasonably predict the occurrence of a pandemic. UKHSA cannot determine an effective delivery schedule and contract term which would be effective during a pandemic to mitigate the risk of reduced uptake.
The possibility of contract modification if the risk materialises.
If a pandemic event or health emergency occurs, then it is highly likely that the contract may need to be modified.
Risk 2:
A new meningococcal strain materialises, which changes the demand for the contracted meningococcal vaccine requiring additional volumes to be procured to provide protection to expanded cohorts.
How the risk may impact on the performance of the contract.
Should there be an increase in demand, then the current ordered volumes and planned delivery schedules would not provide for an expansion in the number of cohorts which need to be covered with MenB immunisations.
Why is it not possible to address the potential impact of such risks?
UKHSA considers available information from experts within UKHSA, JCVI and DHSC. However, UKHSA cannot anticipate the requirements of an unknown risk. The costs to provide contingency volumes for an unknown risk would be disproportionate to the likelihood of the risk materialising.
The possibility of contract modification if the risk materialises:
It would be likely that the contract would be amended if a new meningococcal strain materialises.
How it was run
Official notice- Submission deadline
- —
Timeline
3 Jun 2026 → 30 Jun 2026 · 2 dates- Standstill ends140 days ago3 Jun 2026, 23:59 BST
- Notice published113 days ago30 Jun 2026, 11:02 BST
Notice history
5 events · 3 releases on Find a Tender · since 9 Sept 2025- Transparency notice published9 Sept 2025, 11:08 BSTUK5
- Contract award notice published22 May 2026, 15:42 BSTUK6
- Buyer details updated22 May 2026, 15:42 BST
- Contract signature expected5 Jun 2026, 23:59 BSTscheduled
- Contract details notice published30 Jun 2026, 11:02 BSTUK7
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| GLAXOSMITHKLINE UK LIMITED1 Oct 2026 – 30 Sept 2029 · up to 30 Sept 2030Extensions: The contract may be extended provided that the aggregate extension period shall not exceed 12 months. | £1same award published again · counted once | 22 May 2026standstill to 3 Jun 2026 | Standstill |
| GLAXOSMITHKLINE UK LIMITED | £1 † | — | Awarded |
Contracts
Meningitis B Vaccine (2026) · GLAXOSMITHKLINE UK LIMITED
- Signed
- 10 Jun 2026
- Value
- £1
- Period
- 1 Oct 2026 – 30 Sept 2029 · up to 30 Sept 2030 with extensions
- Status
- active
- Extensions
- The contract may be extended provided that the aggregate extension period shall not exceed 12 months.
4 agreed KPIs: Delivery - Quantity required is delivered on time in full. · Quality - Product delivered does not give rise to a quality complaint. · Supply Chain - Product delivered is fit for purpose. …
- Delivery - Quantity required is delivered on time in full., Measure - Full volume required to be delivered by the end of the month, which can be split into multiple deliveries.
- Quality - Product delivered does not give rise to a quality complaint., Measure - Number of product quality complaints.
- Supply Chain - Product delivered is fit for purpose., Measure - Stock that is rejected or rejectable as detailed in the contract.
- Shelf life - All goods delivered meet the minimum requirement as per the contract specification., Measure - Variance of the shelf life from the specification, and whether this is notified in advance.
Contracting authority & participating public bodies
2 public bodies on the noticeConsortium members and other public bodies
- UK Health Security AgencyContracting authorityPublic authority - central government
Bidders & participating suppliers
1 commercial party on the notice- GLAXOSMITHKLINE UK LIMITEDAwarded supplier
Official documents & specifications (4)
Official links; attachments are not copiedTender pack and attachments
Notices published for this procedure
- Contract details notice Contract details notice on Find a Tender
- Contract award notice Contract award notice on Find a Tender
- Transparency notice Transparency notice on Find a Tender